Evidence map›Paper›PMID 29337401›Full record

ReviewBritish journal of clinical pharmacology2018

Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions.

Thomas Deljehier, Antoine Pariente, Ghada Miremont-Salamé, Françoise Haramburu, Linh Nguyen, Sébastien Rubin, Claire Rigothier, Hélène Théophile

Abstract readReview
In one paragraph

Review in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thomas DeljehierDepartment of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.ORCID 0000-0002-3979-4069
Antoine ParienteDepartment of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.
Ghada Miremont-SalaméDepartment of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.
Françoise HaramburuDepartment of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.
Linh NguyenUniversity of Bordeaux, Bordeaux, France.
Sébastien RubinUniversity of Bordeaux, Bordeaux, France.
Claire RigothierUniversity of Bordeaux, Bordeaux, France.
Hélène ThéophileDepartment of Medical Pharmacology, Regional Pharmacovigilance Centre, CHU Bordeaux, F-33000, Bordeaux, France.ORCID 0000-0002-0611-2519

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following a severe case of rhabdomyolysis in our University Hospital after a co-administration of atorvastatin and fusidic acid, we describe this interaction as this combination is not clearly contraindicated in some countries, particularly for long-term treatment by fusidic acid. All cases of rhabdomyolysis during a co-administration of a statin and fusidic acid were identified in the literature and in the World and Health Organization database, VigiBase

Indexed as

AgedAnti-Bacterial AgentsDatabases, FactualDrug-Related Side Effects and Adverse ReactionsDrug Therapy, CombinationFusidic AcidHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRhabdomyolysisTime FactorsAnti-Bacterial AgentsFusidic AcidHydroxymethylglutaryl-CoA Reductase Inhibitorsdrug interactionsdrug-related side effectsfusidic acidrhabdomyolysisstatin

Identifiers

PMID29337401
PMCPMC5903256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.